XNCR News and Press, Xencor Inc. From 08/16/21

The following slide deck was published by Xencor, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Xencor, Inc. 2021 Q2 - Results - Earnings Call Presentation

Xencor, Inc. (XNCR) Q2 2021 Earnings Conference Call August 4, 2021 16:30 ET Company Participants Charles Liles - Head, Corporate Communications and Investor Relations Bassil Dahiyat - President and Chief Executive Officer John Desjarlais - Chief Scientific Officer John Kuch - Chief Financial...

Image source: The Motley Fool. Xencor, inc (NASDAQ: XNCR) Q2 2021 Earnings Call Aug 4, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Xencor, inc (XNCR) Q2 2021 Earnings Call Transcript

Xencor (NASDAQ:XNCR): Q2 GAAP EPS of $0.87 beats by $1.48. Revenue of $67.4M (+414.9% Y/Y) beats by $49.48M. Based on current operating plans, Xencor expects to have cash to fund research and development programs and operations into 2024; expects to end 2021 with between $475 and $500M in cas...

-- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results f...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release second quarter 2021 financial results after the market closes on We...

INmune Bio (INMB) has entered into a new $15M credit facility to partially fund the buyout of an option held by Xencor (XNCR).Total consideration to be paid to Xencor is $18.3M, comprised of $15M of cash and $3.3M of INmune shares at a price of $17.14 resulting in the issuance of 19...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present a corpor...

Xencor ([[XNCR]] -0.2%) is expected to generate “a useful cash windfall in the coming months,” noted SVB Leerink analyst Geoffrey Porges in reaction to the FDA’s emergency use authorization granted for a COVID-19 therapy developed by GlaxoSmithKline ([[GSK]] -1....

-- Vir Biotechnology and GlaxoSmithKline's investigational SARS-CoV-2 antibody, engineered with the Xencor XmAb ® Fc technology, Xtend™, is authorized for treatment of mild-to-moderate COVID-19 in high-risk adults and pediatric patients -- -- Treatment with sot...